BridgeBio Pharma, Inc. (BBIO) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $2.65B; Long-Term Debt, Maturity, Year OneUSD $588.50M; Long-Term Debt, Maturity, Year TwoUSD $31.63M.
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $2.65B; Long-Term Debt, Maturity, Year OneUSD $588.50M; Long-Term Debt, Maturity, Year TwoUSD $31.63M.
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $2.01B; Long-Term Debt, Maturity, Year OneUSD $40.63M; Long-Term Debt, Maturity, Year TwoUSD $583.76M.
BridgeBio Pharma, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Long-term Debt, Current Maturities USD | Long-term Debt, Gross USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.65B | $588.50M | $31.63M | $770.72M | $14.81M | $584.77M | $639.62M | $22.83M | (m) | $48.87M | (m) | (m) |
| 2026-03-31 | (m) | $2.65B | $588.50M | $31.63M | $770.72M | $14.81M | $584.77M | $639.62M | $22.83M | (m) | $53.43M | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $57.80M | (m) | (m) |
| 2025-12-31 | (m) | $2.01B | $40.63M | $583.76M | $26.88M | $765.97M | $10.06M | $580.03M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $2.01B | $40.63M | $583.76M | $26.88M | $765.97M | $10.06M | $580.03M | (m) | (m) | $61.96M | (m) | (m) |
| 2025-06-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $437.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 19.30% | (m) | (m) | (m) |
| 2024-09-30 | $436.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $435.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $434.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $446.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $441.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $440.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $435.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $430.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $434.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $430.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $103.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $102.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $90.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.65M | (m) |
| 2020-12-31 | $92.42M | $93.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.46M | $92.50M |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.80% | (m) | (m) | (m) |
| 2020-09-30 | $93.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.80% | (m) | (m) | (m) |
| 2020-06-30 | $92.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $92.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $91.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $95.37M | $6.75M | $28.82M | $50.94M | $8.86M | (m) | (m) | (m) | (m) | (m) | (m) | $75.00M |
| 2019-09-30 | $75.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $54.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |